Abstract
Idiopathic hypereosinophilic syndrome (HES) in children is a very rare disorder; certain clinical differences with adult HES have been described, with no pediatric case with the imatinib-responsive FIP1L1-PDGFRA fusion gene reported to date. The authors describe the clinical course of three children with HES in whom FIP1L1-PDGFRA fusion gene was studied and report the first child with this rearrangement.
MeSH terms
-
Adolescent
-
Anti-Inflammatory Agents / therapeutic use
-
Child
-
Female
-
Humans
-
Hypereosinophilic Syndrome / drug therapy
-
Hypereosinophilic Syndrome / epidemiology
-
Hypereosinophilic Syndrome / genetics*
-
Male
-
Oncogene Proteins, Fusion / genetics*
-
Prednisone / therapeutic use
-
Receptor, Platelet-Derived Growth Factor alpha / genetics*
-
Recurrence
-
mRNA Cleavage and Polyadenylation Factors / genetics*
Substances
-
Anti-Inflammatory Agents
-
Oncogene Proteins, Fusion
-
mRNA Cleavage and Polyadenylation Factors
-
FIP1L1-PDGFRA fusion protein, human
-
Receptor, Platelet-Derived Growth Factor alpha
-
Prednisone